Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients

被引：0
|
作者：
Klein, U. [1 ]
Liang, E. [1 ]
Vogel, B. [1 ]
Kolbinger, F. [1 ]
Bruin, G. [1 ]
Lloyd, P. [1 ]
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2013年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1012
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [21] Secukinumab, a novel anti IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays
    Reich, Kristian
    Blauvelt, Andrew
    Armstrong, April
    Fox, Todd
    Huang, Jiaqing
    Liang, Eric
    Karle, Anette
    Spindeldreher, Sebastian
    Bruin, Gerard
    Kolbinger, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB252 - AB252
  • [22] SECUKINUMAB Fully Human Anti-IL-17 Monoclonal Antibody
    Gonzalez-Gonzalez, L. A.
    Foster, C. S.
    DRUGS OF THE FUTURE, 2011, 36 (06) : 441 - 445
  • [23] Population Pharmacokinetics of Xeligekimab: An Anti-IL-17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis
    Meng, Qingheng
    Wang, Wei
    Zhang, Lingxiao
    Shi, Haiyang
    Liu, Hongxia
    Zheng, Qingshan
    Xu, Ling
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (01): : 53 - 65
  • [24] Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab
    Patra, Ashok Kumar
    Nayak, Shreenath
    Moharana, Anandita
    Ojha, Purusottam
    Das, Sanjeet Kumar
    Akhtar, Jabed
    Giri, Bishwaranjan
    Singh, Sujay
    BIOLOGICS-TARGETS & THERAPY, 2024, 18 : 257 - 271
  • [25] Decreased expression of IL-17 pathway genes in blood in patients with plaque psoriasis treated with the anti-IL-17A monoclonal antibody, ixekizumab
    Krueger, J. G.
    Dow, E. R.
    Nantz, E.
    Komocsar, W. J.
    Banerjee, P.
    Leonardi, C.
    Cameron, G. S.
    Banerjee, S.
    Hoffman, R. W.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S18 - S18
  • [26] The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
    Rodriguez Moncada, Rafael
    Vazquez Moron, Juan Maria
    Pallares Manrique, Hector
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (09) : 720 - +
  • [27] The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
    Huppertz, Christine
    Djuric, Marija Curcic
    Hennze, Robert
    Kolbinger, Frank
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S407 - S407
  • [28] The anti-IL-17A-antibody secukinumab does not attenuate ozone induced acute airway neutrophilia in healthy volunteers
    Kirsten, Anne
    Watz, Henrik
    Pedersen, Frauke
    Holz, Olaf
    Smith, Rachel
    Bruin, Gerard
    Koehne-Voss, Stephan
    Magnussen, Helgo
    Waltz, David A.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [29] Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with psoriasis
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Fox, T.
    Huang, J.
    Lloyd, P.
    Bruin, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E166 - E167
  • [30] Rationale for anti-IL-17A treatment in bullous pemphigoid
    Chakievska, L.
    Holtsche, M. M.
    Hammers, C. M.
    Goletz, S.
    Zillikens, D.
    Schultze, F. S.
    Hoelscher, C.
    Schmidt, E.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E31 - E32
12345